Updated monthly
Research Radar
This is a running feed of notable status changes and new findings across the peptide and GLP-1-class compounds we cover — new clinical-trial registrations, regulatory actions, and published studies. It is not a real-time feed; we compile it from public research literature and update it monthly.
2026
AOD-9604 — As of April 2026, AOD-9604 is listed as 'Nominated but Withdrawn' from FDA Category 2 nomination status.
2026
TB-500 — A scoping review in Applied Sciences (MDPI) mapped the Tβ4/TB-500 tissue-repair literature and found direct TB-500 evidence for musculoskeletal applications limited to a single included study.
2025
BPC-157 — A systematic review of BPC-157 for orthopaedic sports medicine applications screened 544 articles and found only 1 clinical study met inclusion criteria, with the remaining 35 eligible studies being preclinical animal models.
2025
Cagrilintide — REDEFINE 1, a 68-week Phase 3 trial in 3,417 adults with obesity/overweight, compared CagriSema against cagrilintide monotherapy, semaglutide monotherapy, and placebo; results presented at the 85th ADA Scientific Sessions reported more than 1 in 5 participants losing 30%+ body weight with CagriSema.
2025
Cagrilintide — REIMAGINE 2, a Phase 3 trial in 2,713 randomized participants with type 2 diabetes, reported significantly greater HbA1c reduction with cagrilintide-semaglutide versus semaglutide alone.
2025
Cagrilintide — Novo Nordisk submitted a New Drug Application to the FDA for CagriSema for weight management.
2025
Epithalon — Cell-line study examined Epitalon in normal epithelial cells, fibroblasts, and breast cancer cell lines, reporting dose-dependent telomere elongation in normal cells via hTERT/telomerase upregulation, while cancer cells showed a different response pattern.
2025
NAD+ (Nicotinamide Adenine Dinucleotide) Precursors — Systematic review and meta-analysis on skeletal muscle mass/function found NMN/NR research promising for age-related sarcopenia but evidence in older adults remains inconclusive.
2025
NAD+ (Nicotinamide Adenine Dinucleotide) Precursors — Geromedicine-focused systematic review of RCTs (2020-2025) compiled completed trials of NAD+ precursors in Alzheimer's disease, mild cognitive impairment, Parkinson's disease, and peripheral artery disease.
2025-2026
NAD+ (Nicotinamide Adenine Dinucleotide) Precursors — Head-to-head human trial published in Nature Metabolism directly compared NMN, NR, and nicotinamide (Nam), finding NMN and NR each approximately doubled circulating NAD+ over 14 days while Nam did not sustain the increase; gut bacteria conversion to nicotinic acid (NA) was implicated as a mechanism.
2025-2026
Retatrutide — TRIUMPH-1 (obesity/overweight), TRIUMPH-4 (obesity + knee osteoarthritis), TRIUMPH-3 (severe obesity + cardiovascular disease), and TRANSCEND-T2D-1 (type 2 diabetes) Phase 3 trials reported topline and detailed results.
2025
Semaglutide — Ozempic approved to reduce risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease; FDA also approved an oral Wegovy tablet based on the Phase III OASIS 4 trial (NCT05564117).
2025
Tesamorelin — FDA approved a supplemental Biologics License Application for Egrifta WR (Tesamorelin F8), a longer-acting formulation requiring weekly rather than daily reconstitution.
2025
Tesamorelin — FDA approved a Prior Approval Supplement for Egrifta SV, removing a discretionary product-release requirement and allowing resumed regular distribution.
2025
Thymosin Alpha-1 — Updated systematic review/meta-analysis of 11 RCTs (1,927 sepsis patients) reported a significant 28-day mortality reduction with Ta1 (OR 0.73, 95% CI 0.59-0.90), while cautioning that evidence reliability remains uncertain.
2025
Tirzepatide — SURMOUNT-5 head-to-head trial published in NEJM reported tirzepatide 15 mg produced approximately 20.2% weight loss versus 13.7% for semaglutide 2.4 mg over 72 weeks.
2024
AOD-9604 — FDA determined AOD-9604 should not be added to the 503A Bulks List for compounding pharmacies, citing limited long-term safety data, peptide impurities, and immunogenicity concerns.
2024
NAD+ (Nicotinamide Adenine Dinucleotide) Precursors — FASEB Scientific Research Conference on NAD Metabolism and Signaling highlighted growing 'bench to clinic' research interest and individual variability in response to NAD+ precursors.
2024
Retatrutide — Phase 2a randomized trial reported retatrutide effects on metabolic dysfunction-associated steatotic liver disease (MASLD).
2024
Semaglutide — Wegovy approved for cardiovascular risk reduction in adults with overweight/obesity and established cardiovascular disease, based on the SELECT trial (17,604 participants).
2024
TB-500 — Metabolism research (Rahaman et al.) reported that TB-500's wound-healing activity may stem from a metabolite, Ac-LKKTE, rather than the parent fragment itself.
2024
Tirzepatide — Zepbound received an additional FDA indication for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial.
Related: all compound research overviews · full vendor rankings · methodology